Golgenia develops therapeutic strategies that target biological processes in the Golgi apparatus to counteract tumor growth and chemotherapy resistance. Its lead compound is being advanced toward a first pilot clinical trial following the Series A financing. The company has an expanded collaboration with Istituto Nazionale Tumori Regina Elena to explore Golgi-related biology and resistance mechanisms. Golgenia recently raised €1.5 million in a Series A round led by Creadd Ventures with participation from Indaco Venture Partners (via Indaco Bio Lombardia / Lombardia Venture STEP) and Ruby Direct Opportunity Fund SCSP. The funds are earmarked to support clinical development activities for its lead program.

Total raised

$2M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2026